Elizabeth Alli received her Ph.D. degree in molecular and cellular pharmacology at the Rutgers University/UMDNJ, Newark, NJ, USA, and completed her postdoctoral fellowship in medicine/oncology at the Stanford University School of Medicine, Stanford, CA, USA. She currently works as an Instructor in medicine/oncology at the same University, where she takes a pharmacological approach to develop anticancer strategies for breast cancer. Specifically, her research focuses on using small molecules to manipulate oxidative DNA damage and repair mechanisms involved in tumorigenesis to develop novel strategies for the treatment and chemoprevention of triple‐negative breast cancers, including hereditary breast cancers due to germline mutations in BRCA1. Dr. Alli’s areas of expertise include tumorigenesis, oxidative DNA damage, base‐excision repair, BRCA1, drug discovery, high‐throughput screening, chemoprevention, chemotherapy, targeted therapy, and breast and ovarian cancers.
Biography Updated on 5 December 2013